Developer docs
API playgroundTry for free, no card

Search company profiles

Idrx

Full company profile

uuid00005yi

Namestring
Idrx
Legal namestring
IDRx, Inc.
Websiteurl
idrx.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

IDRx, Inc. was a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Plymouth, Massachusetts, focused on developing precision oncology therapeutics for genetically defined cancers. The company's scientific premise was that targeting specific genetic drivers of tumors — rather than relying on broad cytotoxic chemotherapy — could yield better efficacy and tolerability in defined patient populations. Its lead clinical asset, IDRX-42, is a small-molecule KIT inhibitor designed to address genetic drivers of KIT in gastrointestinal stromal tumors (GIST), an indication with persistent unmet need after front-line imatinib resistance. A second program, IDRX-73, advanced in parallel as part of a next-generation targeted therapeutics pipeline.

The company operated a classic clinical-stage biotech model: it was pre-revenue, did not commercialize any products, and derived no licensing or royalty income during its independent existence. Its go-to-market posture centered on scientific communication — peer-reviewed publications, oncology conference presentations, and investor relations — rather than field sales or distribution. Customer-facing activity was limited to engaging the scientific and clinical community, with the ultimate end users being GIST cancer patients whose tumors harbor targetable KIT mutations.

IDRx was capitalized through two venture rounds: a $122 million Series A in August 2022 led by Andreessen Horowitz (a16z) and Casdin Capital, and a $120 million Series B in August 2024 led by RA Capital Management, Commodore Capital, and Blackstone Multi-Asset Investing, totaling approximately $242 million raised. In January 2025 (closing February 2025), GSK plc agreed to acquire IDRx for up to $1.15 billion, including upfront and milestone payments, integrating IDRX-42 and the broader pipeline into GSK's oncology division for potential global development and commercialization.

Short descriptiontext

IDRx was a clinical-stage biopharmaceutical company developing precision oncology therapeutics, with lead asset IDRX-42, a KIT inhibitor for gastrointestinal stromal tumor (GIST) patients, acquired by GSK for up to $1.15 billion in early 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology, KIT inhibitors, cancer therapeutics, gastrointestinal stromal tumors, clinical-stage biopharmaceutical
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Precision Oncology Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Potential Commercialization
TypeOne Time License
Description

As a clinical-stage company, IDRx was pre-revenue, focused on developing drug candidates through clinical trials with the goal of achieving regulatory approval and commercializing treatments for cancer patients.

finsmes.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

IDRx is a clinical-stage biopharmaceutical company developing precision oncology drugs, with a primary focus on selective KIT inhibitors for the treatment of gastrointestinal stromal tumors (GIST). The company's lead candidate IDRX-42 targets specific KIT mutations to address unmet needs in GIST therapy, supported by a pipeline that includes additional investigational compounds such as IDRX-73.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

IDRx is a precision cancer drug company developing a pipeline of targeted cancer therapeutics. The company's core products include IDRX-42, a KIT inhibitor for gastrointestinal stromal tumors (GIST), and IDRX-73, another compound in clinical development. Both drug candidates target specific genetic drivers of cancer. The company was acquired by GSK in 2025 as part of GSK's strategy to strengthen its oncology portfolio.

Product and service2 records
1IDRX-42
CategoryPrecision Oncology / Targeted Therapy
Description

Selective KIT inhibitor drug candidate designed to treat gastrointestinal stromal tumors (GIST) by targeting specific KIT mutations; intended for oncologists and patients with GIST, particularly those resistant to existing therapies.

2IDRX-73
CategoryPrecision Oncology / Targeted Therapy
Description

Additional investigational compound in IDRx's clinical-stage oncology pipeline, expanding the company's targeted cancer therapy portfolio beyond the lead IDRX-42 program.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-13
Description

GSK acquired IDRx for up to $1.15 billion including upfront and milestone payments to strengthen its oncology pipeline with targeted cancer therapeutics including IDRX-42

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lilly acquired both Deciphera Pharmaceuticals (Qinlock/GIST) and Theseus Pharmaceuticals (KIT inhibitors) in recent years, making it the most active large oncology acquirer of KIT/GIST assets. Lilly is a direct strategic peer to GSK for oncology pipeline M&A in this category.

TypeBroad incumbent
Description

AstraZeneca operates a broad oncology franchise including targeted therapies across multiple tumor types. While not directly focused on GIST, it is a relevant broad incumbent peer for benchmarking precision oncology pipelines and strategic interest in KIT biology.

TypeBroad incumbent
Description

Novartis markets Gleevec (imatinib), the foundational KIT inhibitor for front-line GIST, and is the originator of the KIT-inhibitor class. While Novartis operates a much broader oncology portfolio, it is the historical standard-of-care competitor in the IDRx indication.

TypeBroad incumbent
Description

Pfizer markets Sutent (sunitinib), an approved multi-kinase inhibitor used in 2L GIST, and operates a broad oncology franchise. Pfizer is a relevant comparable for strategic acquirers and commercial infrastructure post-approval.

TypeEmerging player
Description

Revolution Medicines is a clinical-stage precision oncology company developing targeted therapies against RAS/MAPK pathway and other oncogenic drivers. It is a peer for benchmarking clinical-stage precision oncology company-building, capital efficiency, and deal dynamics in oncology.

TypeEmerging player
Description

Cogent is developing bezuclastinib, a KIT inhibitor in clinical trials for GIST and systemic mastocytosis. Cogent is an emerging direct competitor in the KIT/GIST space and a peer for benchmarking clinical strategy and deal economics.

7Theseus Pharmaceuticals
TypeEmerging player
Description

Theseus developed next-generation KIT inhibitors for GIST and was acquired by Lilly in 2024. Theseus is a closely comparable emerging precision oncology company targeting KIT-driven cancers with a similar strategic exit profile to IDRx.

TypeEmerging player
Description

Mirati developed precision oncology therapies (e.g., Krazati, a KRAS G12C inhibitor) and was acquired by Bristol Myers Squibb in 2024. Mirati is a closely comparable precision oncology company with a similar mid-cap acquisition exit profile to IDRx.

TypeDirect peer
Description

Blueprint Medicines developed and commercializes Ayvakit (avapritinib), an approved KIT/PDGFRA inhibitor for GIST, and is a direct competitor to IDRX-42 in the KIT-mutant GIST space. Blueprint is the most directly comparable precision oncology company targeting the same biology and patient population.

TypeDirect peer
Description

Deciphera developed Qinlock (ripretinib), an approved KIT inhibitor for 4L GIST, and was acquired by Eli Lilly in 2021. Deciphera was a direct GIST competitor to IDRx and the IDRX-42 acquisition by GSK closely mirrors the Lilly–Deciphera strategic logic.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Idrx

Precision Oncology Therapeuticsidrx.com

IDRx was a clinical-stage biopharmaceutical company developing precision oncology therapeutics, with lead asset IDRX-42, a KIT inhibitor for gastrointestinal stromal tumor (GIST) patients, acquired by GSK for up to $1.15 billion in early 2025.

What Idrx does

IDRx, Inc. was a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Plymouth, Massachusetts, focused on developing precision oncology therapeutics for genetically defined cancers. The company's scientific premise was that targeting specific genetic drivers of tumors — rather than relying on broad cytotoxic chemotherapy — could yield better efficacy and tolerability in defined patient populations. Its lead clinical asset, IDRX-42, is a small-molecule KIT inhibitor designed to address genetic drivers of KIT in gastrointestinal stromal tumors (GIST), an indication with persistent unmet need after front-line imatinib resistance. A second program, IDRX-73, advanced in parallel as part of a next-generation targeted therapeutics pipeline.

The company operated a classic clinical-stage biotech model: it was pre-revenue, did not commercialize any products, and derived no licensing or royalty income during its independent existence. Its go-to-market posture centered on scientific communication — peer-reviewed publications, oncology conference presentations, and investor relations — rather than field sales or distribution. Customer-facing activity was limited to engaging the scientific and clinical community, with the ultimate end users being GIST cancer patients whose tumors harbor targetable KIT mutations.

IDRx was capitalized through two venture rounds: a $122 million Series A in August 2022 led by Andreessen Horowitz (a16z) and Casdin Capital, and a $120 million Series B in August 2024 led by RA Capital Management, Commodore Capital, and Blackstone Multi-Asset Investing, totaling approximately $242 million raised. In January 2025 (closing February 2025), GSK plc agreed to acquire IDRx for up to $1.15 billion, including upfront and milestone payments, integrating IDRX-42 and the broader pipeline into GSK's oncology division for potential global development and commercialization.

Idrx firmographics

Firmographics
Name
Idrx
Legal name
IDRx, Inc.
Website
https://idrx.com
Company type
Private
Founded year
2022
Operating status
Acquired
Headcount range
1–10 employees
Short description
IDRx was a clinical-stage biopharmaceutical company developing precision oncology therapeutics, with lead asset IDRX-42, a KIT inhibitor for gastrointestinal stromal tumor (GIST) patients, acquired by GSK for up to $1.15 billion in early 2025.
Ownership category
akta.pro rank

Where Idrx is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Idrx business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Drug Development and Potential Commercialization: As a clinical-stage company, IDRx was pre-revenue, focused on developing drug candidates through clinical trials with the goal of achieving regulatory approval and commercializing treatments for cancer patients.

Go-to-market motion1 record

Marketing channels1 record

Idrx product offering

Product offering

Core offering

IDRx is a clinical-stage biopharmaceutical company developing precision oncology drugs, with a primary focus on selective KIT inhibitors for the treatment of gastrointestinal stromal tumors (GIST). The company's lead candidate IDRX-42 targets specific KIT mutations to address unmet needs in GIST therapy, supported by a pipeline that includes additional investigational compounds such as IDRX-73.

Product overview

IDRx is a precision cancer drug company developing a pipeline of targeted cancer therapeutics. The company's core products include IDRX-42, a KIT inhibitor for gastrointestinal stromal tumors (GIST), and IDRX-73, another compound in clinical development. Both drug candidates target specific genetic drivers of cancer. The company was acquired by GSK in 2025 as part of GSK's strategy to strengthen its oncology portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

  • IDRX-42 Selective KIT inhibitor drug candidate designed to treat gastrointestinal stromal tumors (GIST) by targeting specific KIT mutations; intended for oncologists and patients with GIST, particularly those resistant to existing therapies.
  • IDRX-73 Additional investigational compound in IDRx's clinical-stage oncology pipeline, expanding the company's targeted cancer therapy portfolio beyond the lead IDRX-42 program.

Companies that use Idrx

Customer profile

Segments1 record

Ideal customer profiles1 record

Idrx technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Idrx partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • GSKcoreStrategic or Co-development Partner · 13 January 2025GSK acquired IDRx for up to $1.15 billion including upfront and milestone payments to strengthen its oncology pipeline with targeted cancer therapeutics including IDRX-42

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Idrx competitors and assessment

Company assessment

Broad incumbents

  • Eli Lilly: Lilly acquired both Deciphera Pharmaceuticals (Qinlock/GIST) and Theseus Pharmaceuticals (KIT inhibitors) in recent years, making it the most active large oncology acquirer of KIT/GIST assets. Lilly is a direct strategic peer to GSK for oncology pipeline M&A in this category.
  • AstraZeneca: AstraZeneca operates a broad oncology franchise including targeted therapies across multiple tumor types. While not directly focused on GIST, it is a relevant broad incumbent peer for benchmarking precision oncology pipelines and strategic interest in KIT biology.
  • Novartis: Novartis markets Gleevec (imatinib), the foundational KIT inhibitor for front-line GIST, and is the originator of the KIT-inhibitor class. While Novartis operates a much broader oncology portfolio, it is the historical standard-of-care competitor in the IDRx indication.
  • Pfizer: Pfizer markets Sutent (sunitinib), an approved multi-kinase inhibitor used in 2L GIST, and operates a broad oncology franchise. Pfizer is a relevant comparable for strategic acquirers and commercial infrastructure post-approval.

Emerging players

  • Revolution Medicines: Revolution Medicines is a clinical-stage precision oncology company developing targeted therapies against RAS/MAPK pathway and other oncogenic drivers. It is a peer for benchmarking clinical-stage precision oncology company-building, capital efficiency, and deal dynamics in oncology.
  • Cogent Biosciences: Cogent is developing bezuclastinib, a KIT inhibitor in clinical trials for GIST and systemic mastocytosis. Cogent is an emerging direct competitor in the KIT/GIST space and a peer for benchmarking clinical strategy and deal economics.
  • Theseus Pharmaceuticals: Theseus developed next-generation KIT inhibitors for GIST and was acquired by Lilly in 2024. Theseus is a closely comparable emerging precision oncology company targeting KIT-driven cancers with a similar strategic exit profile to IDRx.
  • Mirati Therapeutics: Mirati developed precision oncology therapies (e.g., Krazati, a KRAS G12C inhibitor) and was acquired by Bristol Myers Squibb in 2024. Mirati is a closely comparable precision oncology company with a similar mid-cap acquisition exit profile to IDRx.

Direct peers

  • Blueprint Medicines: Blueprint Medicines developed and commercializes Ayvakit (avapritinib), an approved KIT/PDGFRA inhibitor for GIST, and is a direct competitor to IDRX-42 in the KIT-mutant GIST space. Blueprint is the most directly comparable precision oncology company targeting the same biology and patient population.
  • Deciphera Pharmaceuticals: Deciphera developed Qinlock (ripretinib), an approved KIT inhibitor for 4L GIST, and was acquired by Eli Lilly in 2021. Deciphera was a direct GIST competitor to IDRx and the IDRX-42 acquisition by GSK closely mirrors the Lilly–Deciphera strategic logic.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Idrx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Idrx leadership team

Management profile

Number of profiles

Profiles10 records

Idrx funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Idrx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Idrx

What does Idrx do?

IDRx is a clinical-stage biopharmaceutical company developing precision oncology drugs, with a primary focus on selective KIT inhibitors for the treatment of gastrointestinal stromal tumors (GIST). The company's lead candidate IDRX-42 targets specific KIT mutations to address unmet needs in GIST therapy, supported by a pipeline that includes additional investigational compounds such as IDRX-73.

Is Idrx a public or private company?

Idrx is a private company. It is classified as corporate owned and is currently acquired.

When was Idrx founded?

Idrx was founded in 2022. It employs 1 to 10 people.

Where is Idrx based?

Idrx is headquartered in Cambridge, United States, in the North America region.

How does Idrx make money?

One revenue line is on record: drug Development and Potential Commercialization.

Who are Idrx's main competitors?

Broad incumbents on record are Eli Lilly, AstraZeneca, Novartis and Pfizer. Emerging players are Revolution Medicines, Cogent Biosciences, Theseus Pharmaceuticals and Mirati Therapeutics. Direct peers are Blueprint Medicines and Deciphera Pharmaceuticals.

Does Idrx have an API?

No public API is recorded for Idrx.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarVivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for MesotheliomaVivace Therapeutics appointed Craig Gibbs as CEO, Ellen Lubman as Chief Business and Strategy Officer, and Tim Clackson to the board. The company will advance VT3989, a TEAD inhibitor, into Phase 3 sTEADfast trial in mesothelioma, with FDA safe-to-proceed granted. The trial is expected to initiate later this year.QuartrGSK (GSK) Jefferies Global Healthcare Conference 2026 summaryGSK presented its strategic portfolio shift toward precision oncology at the Jefferies Global Healthcare Conference 2026, moving away from broad checkpoint inhibitor exploration to focus on validated platforms with higher success probability. The company highlighted continued development of Blenrep with positive DREAMM-7 and DREAMM-8 outcomes, prioritization of dostarlimab in under-served indications, and business development acquisitions including Sierra Oncology, IDRx, and CELLphenomics to strengthen its pipeline and technology capabilities. GSK also reported strong efficacy data for its B7-H4 and B7-H3 antibody-drug conjugates in gynecological cancers, with phase III studies underway.FierceBiotechAt ASCO 2026, a ‘paradigm shift’ for a rare gut cancer loomsGSK presented velzatinib data at ASCO 2026, showing tumor shrinkage in 61% of 24 first-line patients and 38% of 49 second-line patients. The company plans phase 3 trials against Gleevec and Sutent, aiming to redefine standard of care for gastrointestinal stromal tumors.openPR.comEmerging Sub-Segments Transforming the Soft Tissue Sarcoma Market LandscapeThe soft tissue sarcoma market is projected to reach $5.17 billion by 2030, growing at a compound annual growth rate of 8.7%, driven by novel drug approvals, immunotherapy expansion, molecular testing advancements, and increasing demand for personalized treatments. In February 2025, UK-based GSK Plc acquired US biopharmaceutical firm IDRx, Inc. to strengthen its specialty pharmaceuticals division and enhance targeted drug development capabilities, though financial terms were not disclosed. Additionally, US healthcare organization Mercy launched an AI-powered chemotherapy monitoring service in November 2023 that sends daily symptom check-ins to patients and escalates alerts to providers for early intervention.BostonGlobe.comAfter SVB collapse, Jeff Leerink's investment bank leads the packBoston-based Leerink Partners has emerged from the 2023 SVB Financial Group collapse as the top investment bank in biopharma and broader healthcare stock deals, overtaking competitors Jefferies, JPMorgan, and Goldman Sachs for the first time in 2025, according to Dealogic data. The firm nearly doubled its revenue since the SVB turmoil, advised on landmark billion-dollar deals including GSK's acquisition of IDRx and Tourmaline Bio's sale to Novartis, and opened its first international office in London. The article notes ongoing risks to the Greater Boston biotech ecosystem from potential federal research funding cuts, though Leerink projects record revenue for 2026.openPR.comThyroid Cancer Treatment Market 2025 | Latest FDA Approvals, M&A Deals & Research Updates, Clinical Phases - Key Industry Players are Genentech USA, Inc, Blueprint Medicines Corporation, Daiichi SankyThe global thyroid cancer treatment market is projected to grow from US$1.14 billion in 2024 to US$2.94 billion by 2033, a CAGR of 11.2%. Recent M&A activity includes GSK's $1.15 billion acquisition of IDRx and Eli Lilly's $2.5 billion deal for Scorpion Therapeutics, while FDA approvals for cabozantinib and lenvatinib-pembrolizumab are noted.PR NewswireBlueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceBlueprint Medicines Corporation reported first quarter 2025 net product revenues of $149.4 million for AYVAKIT/AYVAKYT, representing 61% year-over-year growth, and raised its full-year 2025 revenue guidance to $700–720 million on the path to a $2 billion target by 2030. The company initiated proof-of-concept studies for BLU-808 in allergic rhinoconjunctivitis and chronic urticaria, and strengthened its cash position by $78.7 million following the sale of its equity investment in IDRx, Inc. after its acquisition by GSK plc. Blueprint expects a year-over-year reduction in cash burn in 2025 while continuing to invest in its prioritized pipeline programs.YahooUK M&A activity down in January amid uncertain US opportunitiesUK healthcare M&A deals fell to 17 in January 2025 from 22 in the same period last year, per Heligan Group. Pharma and life sciences led with 35% of volume, and GSK acquired US biotech IDRx for $1.15bn. Heligan said the drop may reflect changing fund dynamics, not a Q1 slowdown.BloombergGSK Eyes Growth in Cancer Drugs Amid Concern Over PipelineGSK is pursuing growth in its cancer drug business, having completed the $1.15 billion acquisition of biotech IDRx. The deal gives GSK access to an experimental drug for gastrointestinal tumors. GSK's oncology strategy aims to continue growing consistently.NasdaqThe Unstoppable Momentum in Oncology M&AEli Lilly is in advanced talks to acquire Scorpion Therapeutics for up to $2.5 billion, with about $1 billion upfront. GSK acquired IDRx for up to $1.15 billion, focusing on rare cancer therapies. The deals reflect a broader oncology M&A trend driven by financial strength and innovation.